{"title_page": "BP-897", "text_new": "{{Drugbox\n| Verifiedfields = changed\n| verifiedrevid = 386255446\n| IUPAC_name = N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide\n| image = BP-897_structure.png\n\n<!--Clinical data-->\n| tradename =  \n| pregnancy_category =  \n| legal_status =  \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability =  \n| metabolism =  \n| elimination_half-life =  \n| excretion =\n\n<!--Identifiers-->\n| IUPHAR_ligand = 7625\n| CAS_number_Ref = {{cascite|correct|??}}\n| CAS_number = 314776-92-6\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 20PLE5W821\n| ATC_prefix = none\n| ATC_suffix =  \n| PubChem = 3038495\n| ChEMBL_Ref = {{ebicite|changed|EBI}}\n| ChEMBL = 25236\n| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}\n| ChemSpiderID = 2302059\n| StdInChI_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChI = 1S/C26H31N3O2/c1-31-25-11-5-4-10-24(25)29-18-16-28(17-19-29)15-7-6-14-27-26(30)23-13-12-21-8-2-3-9-22(21)20-23/h2-5,8-13,20H,6-7,14-19H2,1H3,(H,27,30)\n| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChIKey = MNHDKMDLOJSCGN-UHFFFAOYSA-N\n\n<!--Chemical data-->\n| C=26 | H=31 | N=3 | O=2 \n| molecular_weight = 417.542 g/mol\n| smiles = COc1ccccc1N3CCN(CC3)CCCCNC(=O)c4ccc2ccccc2c4\n}}\n\n'''BP-897''' is a drug used in scientific research which acts as a moderately selective [[dopamine]] [[D3 receptor|D<sub>3</sub>]] [[Receptor (biochemistry)|receptor]] [[partial agonist]].<ref name=\"pmid10432116\">{{cite journal |vauthors=Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P |title=Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist |journal=Nature |volume=400 |issue=6742 |pages=371\u20135 |date=July 1999 |pmid=10432116 |doi=10.1038/22560 |url=}}</ref> It has mainly been used in the study of treatments for [[cocaine]] addiction.<ref name=\"pmid11270507\">{{cite journal |vauthors=Beardsley PM, Sokoloff P, Balster RL, Schwartz JC |title=The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered |journal=Behavioural Pharmacology |volume=12 |issue=1 |pages=1\u201311 |date=February 2001 |pmid=11270507 |doi= 10.1097/00008877-200102000-00001|url=}}</ref><ref name=\"pmid12847556\">{{cite journal |vauthors=Garcia-Ladona FJ, Cox BF |title=BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction |journal=CNS Drug Reviews |volume=9 |issue=2 |pages=141\u201358 |year=2003 |pmid=12847556 |doi= 10.1111/j.1527-3458.2003.tb00246.x|url=|pmc=6741652 }}</ref><ref name=\"pmid12915863\">{{cite journal |vauthors=Duarte C, Lefebvre C, Chaperon F, Hamon M, Thi\u00e9bot MH |title=Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats |journal=Neuropsychopharmacology |volume=28 |issue=11 |pages=1903\u201315 |date=November 2003 |pmid=12915863 |doi=10.1038/sj.npp.1300276 |url=}}</ref><ref name=\"pmid15226382\">{{cite journal |vauthors=Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M |title=Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=311 |issue=2 |pages=770\u20137 |date=November 2004 |pmid=15226382 |doi=10.1124/jpet.104.071142 |url=}}</ref><ref name=\"pmid15858839\">{{cite journal |vauthors=Gilbert JG, Newman AH, Gardner EL, Ashby CR, Heidbreder CA, Pak AC, Peng XQ, Xi ZX |title=Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors |journal=Synapse (New York, N.Y.) |volume=57 |issue=1 |pages=17\u201328 |date=July 2005 |pmid=15858839 |doi=10.1002/syn.20152 |url=|pmc=3726034 }}</ref><ref name=\"pmid17985117\">{{cite journal |vauthors=Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR, Heidbreder C, Ga\u00e1l J, Gardner EL |title=The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats |journal=Psychopharmacology |volume=196 |issue=4 |pages=533\u201342 |date=March 2008 |pmid=17985117 |doi=10.1007/s00213-007-0986-6 |url=|pmc=3713235 }}</ref><ref name=\"pmid18306190\">{{cite journal |vauthors=Hocke C, Prante O, Salama I, H\u00fcbner H, L\u00f6ber S, Kuwert T, Gmeiner P |title=18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor |journal=ChemMedChem |volume=3 |issue=5 |pages=788\u201393 |date=May 2008 |pmid=18306190 |doi=10.1002/cmdc.200700327 |url=}}</ref>\n\n== References ==\n{{Reflist}}\n\n{{Dopaminergics}}\n\n[[Category:Dopamine agonists]]\n[[Category:Naphthalenes]]\n[[Category:Carboxamides]]\n[[Category:Phenylpiperazines]]\n[[Category:Phenol ethers]]\n[[Category:Experimental drugs]]\n\n\n{{nervous-system-drug-stub}}\n", "text_old": "{{Drugbox\n| Verifiedfields = changed\n| verifiedrevid = 386255446\n| IUPAC_name = N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide\n| image = BP-897_structure.png\n\n<!--Clinical data-->\n| tradename =  \n| pregnancy_category =  \n| legal_status =  \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability =  \n| metabolism =  \n| elimination_half-life =  \n| excretion =\n\n<!--Identifiers-->\n| IUPHAR_ligand = 7625\n| CAS_number_Ref = {{cascite|correct|??}}\n| CAS_number = 314776-92-6\n| ATC_prefix = none\n| ATC_suffix =  \n| PubChem = 3038495\n| ChEMBL_Ref = {{ebicite|changed|EBI}}\n| ChEMBL = 25236\n| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}\n| ChemSpiderID = 2302059\n| StdInChI_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChI = 1S/C26H31N3O2/c1-31-25-11-5-4-10-24(25)29-18-16-28(17-19-29)15-7-6-14-27-26(30)23-13-12-21-8-2-3-9-22(21)20-23/h2-5,8-13,20H,6-7,14-19H2,1H3,(H,27,30)\n| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}\n| StdInChIKey = MNHDKMDLOJSCGN-UHFFFAOYSA-N\n\n<!--Chemical data-->\n| C=26 | H=31 | N=3 | O=2 \n| molecular_weight = 417.542 g/mol\n| smiles = COc1ccccc1N3CCN(CC3)CCCCNC(=O)c4ccc2ccccc2c4\n}}\n\n'''BP-897''' is a drug used in scientific research which acts as a moderately selective [[dopamine]] [[D3 receptor|D<sub>3</sub>]] [[Receptor (biochemistry)|receptor]] [[partial agonist]].<ref name=\"pmid10432116\">{{cite journal |vauthors=Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P |title=Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist |journal=Nature |volume=400 |issue=6742 |pages=371\u20135 |date=July 1999 |pmid=10432116 |doi=10.1038/22560 |url=}}</ref> It has mainly been used in the study of treatments for [[cocaine]] addiction.<ref name=\"pmid11270507\">{{cite journal |vauthors=Beardsley PM, Sokoloff P, Balster RL, Schwartz JC |title=The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered |journal=Behavioural Pharmacology |volume=12 |issue=1 |pages=1\u201311 |date=February 2001 |pmid=11270507 |doi= 10.1097/00008877-200102000-00001|url=}}</ref><ref name=\"pmid12847556\">{{cite journal |vauthors=Garcia-Ladona FJ, Cox BF |title=BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction |journal=CNS Drug Reviews |volume=9 |issue=2 |pages=141\u201358 |year=2003 |pmid=12847556 |doi= 10.1111/j.1527-3458.2003.tb00246.x|url=|pmc=6741652 }}</ref><ref name=\"pmid12915863\">{{cite journal |vauthors=Duarte C, Lefebvre C, Chaperon F, Hamon M, Thi\u00e9bot MH |title=Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats |journal=Neuropsychopharmacology |volume=28 |issue=11 |pages=1903\u201315 |date=November 2003 |pmid=12915863 |doi=10.1038/sj.npp.1300276 |url=}}</ref><ref name=\"pmid15226382\">{{cite journal |vauthors=Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M |title=Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=311 |issue=2 |pages=770\u20137 |date=November 2004 |pmid=15226382 |doi=10.1124/jpet.104.071142 |url=}}</ref><ref name=\"pmid15858839\">{{cite journal |vauthors=Gilbert JG, Newman AH, Gardner EL, Ashby CR, Heidbreder CA, Pak AC, Peng XQ, Xi ZX |title=Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors |journal=Synapse (New York, N.Y.) |volume=57 |issue=1 |pages=17\u201328 |date=July 2005 |pmid=15858839 |doi=10.1002/syn.20152 |url=|pmc=3726034 }}</ref><ref name=\"pmid17985117\">{{cite journal |vauthors=Spiller K, Xi ZX, Peng XQ, Newman AH, Ashby CR, Heidbreder C, Ga\u00e1l J, Gardner EL |title=The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats |journal=Psychopharmacology |volume=196 |issue=4 |pages=533\u201342 |date=March 2008 |pmid=17985117 |doi=10.1007/s00213-007-0986-6 |url=|pmc=3713235 }}</ref><ref name=\"pmid18306190\">{{cite journal |vauthors=Hocke C, Prante O, Salama I, H\u00fcbner H, L\u00f6ber S, Kuwert T, Gmeiner P |title=18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor |journal=ChemMedChem |volume=3 |issue=5 |pages=788\u201393 |date=May 2008 |pmid=18306190 |doi=10.1002/cmdc.200700327 |url=}}</ref>\n\n== References ==\n{{Reflist}}\n\n{{Dopaminergics}}\n\n[[Category:Dopamine agonists]]\n[[Category:Naphthalenes]]\n[[Category:Carboxamides]]\n[[Category:Phenylpiperazines]]\n[[Category:Phenol ethers]]\n[[Category:Experimental drugs]]\n\n\n{{nervous-system-drug-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/BP-897"}
